Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for p53-abnormal endometrial cancer, including uterine serous carcinoma, drawn from the whole corpus: 7 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Distant relapse after early-stage disease despite chemotherapy.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Whether PARP inhibition helps p53-abnormal tumours as it does ovarian cancer.
Low response to immunotherapy in a class that accounts for most deaths.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Endometrial ORR 57.
OS 44.
OS 18.
A milestone in how this cancer is treated.